Accueil > Actualité

New paradigm in the treatment of neuropathic pain

par corneille - publié le , mis à jour le

The French-Polish collaboration between IBMM and Medical College of Jagiellonian University in Kraków (Prof. Pawel Zajdel), fruitful for over 35 years, recently opened up to the teams of Dr Philippe Marin (Institute of Functional Genomics, Université de Montpellier, CNRS, Inserm) and Prof. Christine Courteix (Neuro-Dol, Université de Clermont-Auvergne, Inserm). This larger international collaboration has brought to light the involvement of the 5-HT6 serotonergic receptors and the activation of mTOR (mammalian target of rapamycin) in the treatment of neuropathic pain, a chronic disease for which no treatment is effective to date.
Thus, the use of inverse agonists, synthesized in part in the Green Chemistry and Enabling Technologies research team, could be a new and effective strategy for relieving neuropathic pain and associated cognitive disorders. Preliminary results are reported in the journal Progress in Neurobiology.

Link to the publication :
mTOR activation by constitutively active serotonin6 receptors as new paradigm in neuropathic pain and its treatment. Martin, P.-Y. ; Doly, S. ; Hamieh, A. M. ; Chapuy, E. ; Canale, V. ; Drop, M. ; Chaumont-Dubel, S. ; Bantreil, X. ; Lamaty, F. ; Bojarski, A. ; Zajdel, P. ; Eschalier, A. ; Marin, P. ; Courteix, C., Prog. Neurobiol. 2020, 101846